CTOs on the Move

Xenocor

www.xenocor.com

 
Bringing to market revolutionary laparoscopic technologies which extend the benefits of minimally invasive surgery to hundreds of millions of people worldwide.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.xenocor.com
  • 630, Komas Drive
    Salt Lake City, UT USA 84108
  • Phone: 844.936.6267

Executives

Name Title Contact Details

Similar Companies

Osteal Therapeutics

Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.

IVX Health

Our local centers provide infusion care such as Remicade, Ocrevus, and Entyvio and injections like Xolair and Fasenra for patients with ongoing conditions.

Ryan TrueHealth

Ryan TrueHealth is a Wilton, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PBN Pharma

PBN Pharma is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.